{"entity":{"id":"biofidelity","kind":"company","name":"Biofidelity","aka":["Biofidelity Ltd"],"tldr":"A Cambridge company developing Enspyre, a way of enriching tumour DNA so blood tests for leftover cancer need far less sequencing.","summary":"Biofidelity Ltd of Cambridge, UK, is the affiliation of the authors of the 2026 Scientific Reports study of Enspyre, a mutation-enrichment ctDNA assay tested on diluted lung cancer plasma.","asOf":"2026-11-04","links":[{"label":"Labrousse et al., Enspyre (Scientific Reports 2026)","url":"https://doi.org/10.1038/s41598-026-57421-5"}],"tags":[],"related":[],"cancers":[],"sections":["diagnostics"],"technologies":["mrd-testing","liquid-biopsy"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":["paper-labrousse-enspyre-sci-rep-2026"],"journals":[],"dependsOn":[],"notes":[],"hq":"Cambridge","country":"GB","companyType":"diagnostics","investors":[],"funding":[]},"route":"/companies/biofidelity/","neighbours":{"section":[{"id":"diagnostics","kind":"section","name":"Diagnostics & Biomarkers","route":"/fronts/diagnostics/"}],"technology":[{"id":"liquid-biopsy","kind":"technology","name":"Liquid biopsy (ctDNA)","route":"/technologies/liquid-biopsy/"},{"id":"mrd-testing","kind":"technology","name":"MRD / molecular residual disease testing","route":"/technologies/mrd-testing/"}],"paper":[{"id":"paper-labrousse-enspyre-sci-rep-2026","kind":"paper","name":"Enrichment of mutated DNA enables ultra-sensitive ctDNA detection in NSCLC using shallow targeted sequencing","route":"/key-papers/paper-labrousse-enspyre-sci-rep-2026/"}],"drug":[{"id":"enspyre-mrd","kind":"drug","name":"Enspyre","route":"/drugs/enspyre-mrd/"}]}}